



Excellence in Oncology Care

13-15 NOVEMBER 2026

INTERCONTINENTAL FESTIVAL CITY
DUBAI, UNITED ARAB EMIRATES

ACCESS. COLLABORATE. EDUCATE.

BREAST CANCER SESSION



In Conjunction With



In collaboration with



ARAB SCHOOL
OF UROLOGY

Congress Secretariat



cancercongress.ae

#EIOC2026



 14 November 2026 (Saturday)	 08:30 – 17:00 Hrs GST	 In Person	 Al Ras 3
---	---	--	---

08:25 – 08:30	Opening Remarks Shaheenah Dawood, UAE
Plenary Session Chairpersons: Cherian Thampy, UAE Aladdin Marraoui, UAE	
08:30 – 08:50	A Year in Review: What Have We Learned? Erica Mayer, USA
08:50 – 09:10	Escalating and De-escalating Surgery in Breast Cancer Nita Nair, India
SESSION 1: HR-Positive Breast Cancer Chairpersons: Susheel Kumar, UAE Ali Chamseddine, UAE Tarek AlKhouri, UAE	
09:10 – 09:30	SERENA 6: Precision Oncology Paving the Way! Francois-Clement Bidard, France
09:30 – 09:45	Hormone Receptor-Positive, HER2-Negative Early Breast Cancer Satellite Symposium by Novartis TBA
09:45 – 10:00	New Targets in HR +Ve Breast Cancer: Where is the Future Headed TBA
10:00 – 10:15	How Much and How Long Do We Need Endocrine Therapy for EBC? Hamdy Abdul Azim, Egypt
10:15 – 10:45	Panel Discussion: Giredestrant and Oral SERDS in HR+ Treatment Paradigm - Satellite Symposium by Roche Moderator: Maroun El Khoury, UAE Speaker: Shaheenah Dawood, UAE Panel: Batool Aboud, UAE Hala Abdellatif, UAE Ramanujam Singarachari, UAE Sonia Otsmane, UAE
10:45 – 11:00	Coffee Break

11:00 – 11:15	Is ER-Low a Distinct Entity? Nitesh Rohatgi, India
11:15 – 11:45	Tumor Board: Challenging Cases in HR +Ve EBC Moderator: Hamdy Azim, Egypt Panel: Javier Cortes, Spain Tarkan Yetisyigi, Bahrain Hazem Assi, Lebanon Rajeev Kaushal, UAE Fady Geara, UAE Mohanad Diab, UAE Husam Marashi, UAE Ramanujam Singarachari, UAE Francois-Clement Bidard, France
11:45 – 12:00	Breast Truqap - (HR)-positive, HER2-negative Advanced or Metastatic Breast Cancer - Satellite Symposium by AZ Javier Cortes, Spain
12:00 – 12:15	Breast Enhertu - HER2-positive and HER2-low breast - Satellite Symposium by AZ Shaheenah Dawood, UAE
12:15 – 12:30	Is There Still A Role for Cleopatra in HER2 Positive MBC? Javier Cortes, Spain
SESSION 2: HER2 Positive Breast Cancer Chairpersons: Kakil Rasul, Qatar Salsabil Ibrahim, UAE Ozge Keskin, Bahrain	
12:30 – 12:45	Incorporating CTDNA Monitoring in Breast Cancer: Where are we in 2026? Peter Fasching, Germany
12:45 – 13:15	Tumor Board: Challenging Cases in HER2 Positive MBC Moderator: Shona Nag, India Panel: Francois-Clement Bidard, France Suhaila Al Farsi, Oman Medhat Faris, UAE Sinem Akbas, Bahrain Francois Calaud, Qatar Syed Monawer Karim, UAE Sonia Otsmane, UAE Riyad Bendardaf, UAE
13:15 – 13:30	Hormone Receptor-Positive, HER2-Negative Breast Cancer - Satellite Symposium by Novartis TBA
13:30 – 14:30	Lunch Break
14:30 – 14:45	Optimizing Treatment Strategies in 2L + HR+ / HER2- Metastatic Breast Cancer: Understanding and Overcoming Resistance - Satellite Symposium by Menarini Javier Cortes, Spain
14:45 – 15:00	Beyond 'What If' to 'What Is': Oncotype DX and the Dawn of Personalized Oncology - Satellite Symposium by Newbridge Shaheenah Dawood, UAE

15:00 - 15:30

Tumor Board: Challenging Cases in HER2 Positive EBC

Moderator: Maha Al Sindi, Bahrain

Panel: Mehdi Afrit, UAE | Javier Cortes, Spain | Mohsen Mokhtar, Egypt
Mourad Salam, UAE | Peter Fasching, Germany | Maroun El Khoury, UAE
Marwan Ghosn, UAE | Dina Hamza, UAE

15:30 - 16:10

EBC MBC Topic - **Satellite Symposium by Lilly**
Shaheenah Dawood, UAE

SESSION 3: Triple Negative Breast Cancer and Novel Therapeutics

Chairpersons: **Falah Al Kathib, UAE | Amir Abdelazim, Kuwait | Nihal Yildirim, UAE**

16:10 - 16:40

Tumor Board: Challenging Cases in TNBC (Early-Stage and Metastatic)

Moderator: Fathi Azribi, UAE

Panel: Javier Cortes, Spain | Ozge Keskin, Bahrain | Bharadwaj Ponnada, UAE
Ahmed Saadeddin, KSA | Susheel Kumar, UAE | Farooq Latif, UAE
Rham Zaki Ahmed, UAE | Manuelita Mazza, UAE | Dima Abdul Jabbar, UAE

16:40 - 16:55

How Do We Optimally Integrate ADCs in TNBC?

Rebecca Dent, Singapore

16:55 - 17:00

Closing Remarks